v3.26.1
Certain transactions - Summary of Assets Acquired, liabilities Assumed (Detail) - Emalex Biosciences [Member]
$ in Millions
Jun. 10, 2026
USD ($)
Asset Acquisition [Line Items]  
Cash consideration for outstanding shares, net of working capital adjustments $ 696
Transaction costs 8
Total consideration allocated 704
Other current assets 2
Deferred income taxes 134
Valuation allowance (134)
Accrued expenses (18)
Other liabilities (4)
Total identifiable assets and liabilities acquired (20)
Acquired IPR&D $ 724